THE IMPORTANCE OF ENDOTHELIAL DYSFUNCTION FOR THE DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION AND NEW THERAPEUTIC OPTIONS
Abstract
Background. Pulmonary arterial hypertension may exist as a primary condition or as a secondary condition, most commonly with collagen vascular disease. Patients with pulmonary arterial hypertension usually have bad prognosis as the effectiveness of conventional treatment is poor. New knowledge about importance of endothelial dysfunction in development of pulmonary arterial hypertension has opened a wide field of possible new treatment options.
Conclusions. Endothelial dysfunction in pulmonary vascular bed is characterised by an inappropriate release of vasoactive substances from endothelium producing vasoconstriction, remodeling of arterial wall and increased local tendency for thrombosis. Several new drugs have been already tested in clinical case-controlled studies: prostacyclin and its analogues applied intravenously or in inhalations, inhaled nitric oxide and drugs which increase nitric oxide concentration such as sildenafil and l-arginine, endothelin receptors antagonists in tablets and tromboxane antagonist in tablets. Only tromboxane antagonist was shown to be ineffective whereas all other drugs were effective at least in certain subgroups of patients. New clinical trials will give answer not only in respect to the comparative efficacy of the drugs mentioned earlier and their combinations but also to the recognition of factors that determine the success of treatment in individual patient.
Downloads
References
Meyerick B. The pathology of pulmonary hypertension. Clin Chest Med 2001; 22: 393–404.
Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22: 385–91.
Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the physiology and treatment management of pulmonary hypertension. Cardiovasc Res 1999; 44: 274–82.
Rubany GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22: Suppl 4: S1–S14.
Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension gene (PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737–44.
Tuder RM, Cool CD, Y M, Taraseviciene-Stewart L. The pathobiology of pulmonary hypertension: Endothelium. Clin Chest Med 2001; 22: 405–18.
Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau G. The pathobiology of pulmonary hypertension: The role of platelets and thrombosis. Clin Chest Med 2001; 22: 451–9.
McAdam BF, Catella-Lawson F, Mardini IA et al. Systemic biosynthesis of prostacyclin in cyclooxygenase(COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1996; 96: 272–7.
Kerins DM, Murray R, FitzGerald GA. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Prog Hemostasis Thromb 1991; 10: 307–37.
Badesh DB, Orton EC, Yapp LM et al. Decreased arterial wall prostaglandin production in neonatal calves with severe pulmonary hypertension. Am J Respir Cell Mol Biol 1989; 1: 489–98.
Christman BW, McPreshon CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacycline metabolities in pulmonary hypertension. N Engl J Med 1992; 327: 70–5.
Tuder RM, Cool CD, Geraci ME et al. Prostacyclin syntase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Crit Care Med 1999; 159: 1925–36.
Max M, Roissant R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur J Pediatr 1999; 158: Suppl 1: S23–6.
Fridman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782–4.
Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109–42.
Ignarro LJ, Buga GM, Woods KS et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1997; 84: 9265–9.
Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxyde inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057– 8.
Rudic RD, Shesely EG, Meada N et al. Direct evidence of importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998; 101: 731–6.
Shaul PW. Nitric oxide in the developing lung. Adv Pediatr 1995; 42: 367– 414.
Fike CD, Kaplowitz MR, Thomas J et al. Chronic hypoxia decreases nitric oxide production and endothelial nitric oxide synthase in newborn pig lungs. Am J Physiol 1998; 274: L517–26.
Johns RA, Linden JM, Peach MJ. Endothelium-dependent relaxation and cyclic GMP accumulation in rabit pulmonary artery are selectively impaired by moderate hypoxia. Circ Res 1989; 65: 1508–15.
Giad A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lung of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214–21.
Cella G, Belloto F, Tona F et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120: 1226–30.
McQuillan LP, Leung GK, Marsden PA et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994; 267: H1921–7.
Taylor SG, Weston AH. Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from vascular endothelium. Trend Pharmacol Sci 1988; 9: 72–4.
Triggle CR, Dong H, Waldron GJ et al. Endothelium derived hyperpolarizing factor(s): species and tissue heterogenity. Clin Exp Pharmacol Physiol 1999; 26: 176–9.
Campbell WB, Gebremedhin D, Pratt PF et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78: 415–23.
Ward JP, Aaronson PI. Mechanisms of hypoxic pulmonary vasoconstriction: can anyone be right? Respir Physiol 1999; 115: 261–71.
Yanagisava M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–5.
Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 166: 1081–98.
Sakurai T, Yanagasikawa M, Takuwa H et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990; 348: 732–5.
McEwan PE, Valdenaire O, Sutherland L et al. A non-radioactive method for localisation of endothelin receptor mRNA in situ. J Cardiovasc Pharmacol 1998; 31: Suppl 1: S443–6.
La M, Reid JJ. Endothelin-1 and regulation of vascular tone. Clin Exp Pharmacol Physiol 1995; 22: 315–23.
Shetty SS, Toshikazu O, Webb RL et al. Functional distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun 1993; 191: 459–64.
Giad A, Polak JM, Gaitone V et al. Distribution of endothelin-like immunoreactivity and mRNA in the developing and adult human lung. Am J Resp Cell Mol Biol 1991; 4: 50–8.
Goldie RG. Endothelin receptor subtype: distribution and function in the lung. Pulm Pharmacol Ther 1998; 11: 89–95.
Raffestin B, Andot S, Eddahibi S et al. Pulmonary vascular response to endothelin in rats. J Appl Physiol 1991; 70: 567–74.
Sun SD, Gladson C, Chen YF et al. Chronic hypoxia increases the number of endothelin-1 and endothelin-A receptor positive vascular and alveolar cells in rat lung. Circulation 1994; 90: 1–152.
Li H, Elton TS, Chen YF et al. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994; 266: L553–60.
Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001; 2: 90–101.
Vapataalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 2001; 7: 1075–85.
Higenbottan TW, Laude EA. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension. Chest 1998; 114: S72–9.
Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of randomized trial. Ann Intern Med 1990; 112: 485–91.
Barst RJ, Rubin LJ, McGoon MD et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin (see comments). Ann Intern Med 1994; 121: 409–15.
Higenbottam T, Butt AY, McMahon A et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151–5.
Shapiro SM, Oudiz RJ, Cao T et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343–9.
Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in aptients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–4.
Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double blind placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496–502.
Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9.
Michelakis E, Tymchak W, Lien D et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398– 403.
Ghofrani HA, Wiedman R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002; 360: 895–90.
Nagaya N, Uematsu M, Oya H et al. Short-term oral administration of Larginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001; 163: 887–91.
Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 119–23.
Rubin LJ, Badesh DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.
Langleben D, Christman BW, Barst RJ et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002; 143: E4.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
